CERO THERAPEUTICS HOLDINGS, INC.

Phoenix Biotech Acquisition Corp. (Nasdaq: PBAX), sponsored by Phoenix Biotech Sponsor LLC, is a blank-check company that completed its initial public offering in 2021 with a stated focus on the life sciences and biotechnology sector. In June 2023, PBAX filed an 8-K with the SEC disclosing material developments related to its proposed business combination with Cero Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company developing engineered T-cell receptor therapies targeting solid tumors and other cancers. The filing reflects PBAX's ongoing de-SPAC process as the combined entity advances toward operating under the Cero Therapeutics Holdings name. Sign up at SpacDesk for full filing history, deal timelines, and comprehensive SPAC analytics.